Investment Rating - The industry rating is "Outperform the Market" [8] Core Insights - The top-level policy for traditional Chinese medicine (TCM) has been clarified, emphasizing high-quality development and supporting industry leaders. The "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" was released on February 6, 2026, outlining the development framework for the next five years. The plan highlights the importance of leading companies and innovation in driving industry growth [5][16][21]. - The TCM sector is expected to experience a turning point due to policy support, improved consumer environment, declining raw material prices, and inventory clearance. Key companies to watch include brand TCM firms like China Resources Sanjiu, Dong-E E-Jiao, Jiangzhong Pharmaceutical, and Mayinglong, as well as innovative TCM drug companies like Yiling Pharmaceutical and Fangsheng Pharmaceutical [5][22]. Market Review - In the week from February 2 to February 6, 2026, the CITIC Pharmaceutical Index rose by 0.3%, outperforming the CSI 300 Index by 1.7 percentage points, ranking 12th among CITIC's primary industry classifications. Since the beginning of 2026, the CITIC Pharmaceutical and Biotech sector index has increased by 3.3%, also outperforming the CSI 300 Index by 3.0 percentage points, ranking 19th [4][25]. - The top five performing stocks during this week were: Guangshentang (+29.8%), Haixiang Pharmaceutical (+18.6%), Meidixi (+18.0%), Tianzhihang (+17.6%), and Saike Xide (+14.5%) [4][39]. Short-term Investment Thoughts - The pharmaceutical sector has shown signs of recovery after a period of adjustment, with market sentiment expected to reverse around the Spring Festival. The performance of traditional Chinese medicine has been particularly strong, likely due to the recent policy announcements. The report suggests focusing on innovative drugs, medical devices, and companies benefiting from domestic demand [6][22]. - Recommended stocks for February include Heng Rui Medicine, Kangfang Biotech, Baiji Shenzhou, Ying'en Biotech, Tiger Medical, Microelectrophysiology, Huana Pharmaceutical, and Haite Biotech [6][12].

Group 1 - The core viewpoint of the news is the release of the "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" by eight departments, which aims to establish a collaborative development system for the entire industry chain by 2030, enhancing supply capabilities and technological breakthroughs [1] - The plan emphasizes the importance of digital transformation and green transition in the traditional Chinese medicine industry, with leading companies accelerating the construction of smart factories and upgrading production processes [1] - Guangzhou Pharmaceutical Group's Baiyunshan Zhongyi Pharmaceutical was recognized as the only traditional Chinese medicine manufacturer in the "2025 Advanced Intelligent Factory List" due to its systematic breakthroughs in digital transformation [1] Group 2 - The research and development vitality of traditional Chinese medicine companies is being released, with several innovative Class 1 traditional Chinese medicine products expected to be approved for market launch in 2025, including Jiangsu Kangyuan Pharmaceutical's and Jianmin Pharmaceutical's products [2] - Hunan Fangsheng Pharmaceutical has stated that the implementation plan will significantly promote the development of innovative traditional Chinese medicine, and the company plans to increase investment in this area to strengthen its core competitiveness [2] - Local governments are also leveraging industrial funds to attract social capital, with Yunnan Province establishing a 10 billion yuan traditional Chinese medicine industry development fund to enhance the industry ecosystem [2] Group 3 - Since 2025, the traditional Chinese medicine sector has faced performance pressure due to weak sales in pharmacy and hospital channels, leading to a divergence in the performance of listed companies [3] - The OTC (over-the-counter) sector's leading companies have shown resilience, and the industry is undergoing a painful transition in its development model, with a focus on diversified channels and high clinical value being crucial for future success [3] - The implementation plan supports the cultivation of leading enterprises and encourages the establishment of industrial funds, aiming for a healthy ecosystem that integrates large, medium, and small enterprises [3]

Group 1 - The core point of the announcement is that Hunan Fangsheng Pharmaceutical Co., Ltd.'s subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., has received a Drug Production License from the Guangdong Provincial Drug Administration, allowing it to act as the marketing authorization holder for the drug Riluzole Tablets [1][2] - The Drug Production License is valid until January 26, 2031, and the production address is located in Changsha, Hunan Province, with the entrusted product being Riluzole Tablets [1] - The license is expected to help the company and its subsidiary integrate and allocate production and sales resources, improve capacity utilization, and reduce production costs [2] Group 2 - The short-term impact of obtaining the Drug Production License on the company's performance is not expected to be significant [2] - The pharmaceutical industry is characterized by uncertainties due to market conditions, industry policies, and supply-demand relationships, which can affect the production and sales of pharmaceutical products [2]

3、美团：拟7.17亿美元收购叮咚 美团2月5日公告，公司拟以7.17亿美元收购中国大陆领先的生鲜电商企业叮咚的全部已发行股份。根据 协议，转让方可从目标集团提取不超过2.8亿美元的资金，但需确保目标集团净现金不低于1.5亿美元。 此次收购将使目标公司成为美团的间接全资附属公司，其财务业绩将并入美团的财务报表。 4、天汽模：筹划购买东实股份股权 股票停牌 天汽模2月5日公告，公司正在筹划通过发行股份及支付现金的方式购买东实汽车科技集团股份有限公司 股权并募集配套资金，预计构成重大资产重组。公司股票自2026年2月6日起停牌，预计在不超过10个交 易日内披露交易方案。若公司未能在上述期限内召开董事会审议并披露交易方案，公司股票将于2026年 3月2日开市起复牌并终止筹划相关事项。 5、两连板协鑫集成：公司暂未获得"太空光伏"领域的相关订单 今日聚焦 1、百度集团：董事会已批准一项新的50亿美元股份回购计划 百度集团2月5日公告，董事会已批准一项新的50亿美元股份回购计划及一项股息政策，旨在进一步提升 股东回报。 2、太极实业：子公司十一科技预中标华虹FAB9B项目投标报价37.78亿元 太极实业2月5日公告，子 ...

Group 1 - The company Fangsheng Pharmaceutical announced that its subsidiary GuangDong Fangsheng Ronghua Pharmaceutical Co., Ltd. has received a Drug Production License from the Guangdong Provincial Drug Administration [2] - The license allows the subsidiary to act as the marketing authorization holder for the production of Riluzole tablets, with a validity period until January 26, 2031 [2]

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a Drug Production License from the Guangdong Provincial Drug Administration for its subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., allowing it to act as the marketing authorization holder for RuLuGuoLi tablets [1] Group 1 - The acquisition of the Drug Production License will help the company and its subsidiary integrate and allocate production and sales resources [1] - This license is expected to improve capacity utilization and reduce production costs for the company [1] - The short-term impact on the company's performance is not expected to be significant following the receipt of the Drug Production License [1]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-009 湖南方盛制药股份有限公司 关于控股子公司获得《药品生产许可证》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，湖南方盛制药股份有限公司（以下简称"公司"或"方 盛制药"）控股子公司广东方盛融华药业有限公司（以下简称"方 盛融华"）收到广东省药品监督管理局颁发的《药品生产许可证》， 同意方盛融华作为药品上市许可持有人，方盛制药作为受托方, 受托产品为瑞卢戈利片。具体情况如下： 一、《药品生产许可证》基本情况 企业名称：广东方盛融华药业有限公司 分类码：Bh 法定代表人：方传龙 企业负责人：欧阳 质量负责人：罗积安 有效期至：2031年1月26日 生产地址和生产范围： 受托方是湖南方盛制药股份有限公司，生产地址是：湖南省 长沙市麓松路 789 号，受托产品为瑞卢戈利片（仅限上市注册）。 二、对上市公司的影响及风险提示 社会信用代码：91440 ...

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a Drug Production License from the Guangdong Provincial Drug Administration for its subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., allowing it to act as the marketing authorization holder for RuLuGuoLi tablets [1] Group 1 - The acquisition of the Drug Production License will help the company and its subsidiary integrate and allocate production and sales resources [1] - This license is expected to improve capacity utilization and reduce production costs for the company [1] - The short-term impact on the company's performance is not expected to be significant following this license acquisition [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a Drug Production License from the Guangdong Provincial Drug Administration for its subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., allowing it to hold the marketing authorization for RuLuGuoLi tablets [1] Group 1 - The Drug Production License enables the company and its subsidiary to integrate and allocate production and sales resources [1] - This development is expected to improve capacity utilization and reduce production costs [1] - The immediate impact on the company's financial performance is not expected to be significant [1]